Today it was announced that Rallybio had chosen to discontinue its development of RLYB212 for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). This is a rare maternal disorder where the mother's immune system produces antibodies that attack...
Rhythm Pharmaceuticals just reported today that it had achieved positive results from its pivotal phase 3 TRANSCEND study evaluating the use of setmelanotide, a melanocortin-4 receptor agonist, for the treatment of patients with acquired hypothalamic obesity. This is...
Just several days ago, BeiGene suffered a huge blow for its pipeline, in that its anti-TIGIT antibody ociperlimab (BGB-A1217), would not likely be able to achieve the primary endpoint of its phase 3 AdvanTIG-302 trial. The whole point of...
It was just announced that Sangamo Therapeutics entered into a licensing agreement with Eli Lilly to advance a proprietary STAC-BBB AAV capsid. This is to be used by the big pharma to develop up to five potential neurological disorder...
It was announced today that Aldeyra Therapeutics had received a Complete Response Letter or CRL from the FDA of its drug reproxalap for the treatment of patients with dry eye disease. This was a huge blow to the biotech,...
Corcept Therapeutics is on a roll the last month, because it had been able to establish two key events from its pipeline. For starters, it was able to report that it had met the primary endpoint of its pivotal...
